Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-08-28FDA Approved: FOSPHENYTOIN — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for fosphenytoin sodium (Fosphenytoin) from Fresenius Kabi USA, LLC. The action confirms an approved…
-
FDA approval · 2020-08-26FDA Approved: OXCARBAZEPINE — Supplemental Application (Advagen Pharma Limited)
FDA approved a supplemental application for oxcarbazepine from Advagen Pharma Limited.
-
FDA approval · 2020-08-26FDA Approved: OXCARBAZEPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for oxcarbazepine filed by Sun Pharmaceutical Industries, Inc. (ANDA077794).
-
FDA approval · 2020-08-25FDA Approved: OXCARBAZEPINE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved a supplemental application for oxcarbazepine from Glenmark Pharmaceuticals Inc., USA. This action represents a regulatory u…
-
FDA approval · 2020-08-21FDA Approved: GABAPENTIN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for gabapentin from Amneal Pharmaceuticals LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-08-19FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal (lamotrigine) from GlaxoSmithKline.
-
FDA approval · 2020-08-19FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal (lamotrigine) filed by GlaxoSmithKline LLC.
-
FDA approval · 2020-08-19FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal ODT (lamotrigine) from GlaxoSmithKline LLC, adding or updating the orally disintegratin…
-
CLINICAL_TRIALS trial_result · 2020-08-19Clinical Trial Update: Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy [Phase 4]
Phase 4 open-label safety and efficacy study of levetiracetam in epilepsy (partial seizures) completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-18Clinical Trial Update: Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study [Phase 1, Phase 2]
A crossover study comparing Diazepam Buccal Film to Diastat Rectal Gel in epilepsy patients; completed with results posted in 2020.
-
FDA approval · 2020-08-17FDA Approved: DIAZEPAM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for diazepam from Hikma Pharmaceuticals USA Inc., updating the approved product under the existi…
-
FDA approval · 2020-08-17FDA Approved: GABAPENTIN — Original Application (Zhejiang Yongtai Pharmaceutical Co., Ltd)
FDA approved the original application for gabapentin from Zhejiang Yongtai Pharmaceutical Co., Ltd., authorizing a generic gabapentin produc…
-
CLINICAL_TRIALS trial_result · 2020-08-13Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures [Phase 3]
Phase 3 trial assessing long-term adjunctive lacosamide in adults with partial-onset seizures; study completed with results posted in 2020.
-
FDA approval · 2020-08-07FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DILANTIN Extended Phenytoin Sodium filed by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2020-07-30Clinical Trial Update: Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures [Phase 3]
A Phase 3 trial evaluating add-on levetiracetam for efficacy and tolerability in pediatric patients with refractory partial onset seizures h…
-
FDA approval · 2020-07-28FDA Approved: GABAPENTIN — Supplemental Application (Granules Pharmaceuticals Inc)
FDA approved a supplemental application for gabapentin submitted by Granules Pharmaceuticals Inc.
-
FDA approval · 2020-07-28FDA Approved: LEVETIRACETAM — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for an oral levetiracetam product from Camber Pharmaceuticals, Inc., under an ANDA.
-
FDA approval · 2020-07-24FDA Approved: LEVETIRACETAM — Supplemental Application (Aryeh Pharma corp)
FDA approved a supplemental application for levetiracetam from Aryeh Pharma Corp under ANDA 091485.
-
CLINICAL_TRIALS research · 2020-07-22Clinical Trial Update: Validation of Criteria for Identification of Epileptiform Discharges in EEG Recordings of Patients With Epilepsy
A completed clinical trial update focused on validating criteria to identify epileptiform discharges in EEG recordings from epilepsy patient…
-
CLINICAL_TRIALS trial_result · 2020-07-22Clinical Trial Update: Transcranial Electrical Neuromodulation for Suppressing Epileptiform Discharges [NA]
Phase NA/terminated clinical trial investigating transcranial electrical neuromodulation to suppress epileptiform discharges in epilepsy.
-
CLINICAL_TRIALS trial_result · 2020-07-16Clinical Trial Update: Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy [Phase 3]
Phase 3 follow-up trial assessing long-term safety and efficacy of brivaracetam in epilepsy has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-07-15Clinical Trial Update: Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. [Phase 2, Phase 3]
A Phase 2/Phase 3 study assessing the safety and tolerability of intravenous lacosamide in children with epilepsy has completed with results…
-
FDA approval · 2020-07-11FDA Approved: LEVETIRACETAM — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for levetiracetam in sodium chloride (LEVETIRACETAM IN SODIUM CHLORIDE) from Eugia US LLC, adding a …
-
FDA label_change · 2020-07-06FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for divalproex sodium from Zydus Pharmaceuticals USA Inc. to update the product labeling.
-
FDA approval · 2020-07-06FDA Approved: LEVETIRACETAM IN SODIUM CHLORIDE — Original Application (Nexus Pharmaceuticals LLC)
FDA approved a generic levetiracetam in sodium chloride (ANDA) from Nexus Pharmaceuticals LLC.